Editas Medicine, Inc.

EDIT Nasdaq CIK: 0001650664

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 11 HURLEY ST., CAMBRIDGE, MA, 02141
Mailing Address 11 HURLEY ST., CAMBRIDGE, MA, 02141
Phone 617-401-9000
Fiscal Year End 1231
EIN 464097528

Financial Overview

FY2025

$341.59M
Total Assets
$27.29M
Stockholders' Equity
$146.65M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 27, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
10-K Annual financial report March 9, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC

Annual Reports

10-K March 9, 2026
  • Positive preliminary clinical data for EDIT-301, showing favorable safety and initial efficacy signals, leading to expanded patient cohorts.
  • Strong cash position of $420 million as of December 31, 2025, providing an estimated cash runway of over two years.
View Analysis

Insider Trading

SELL 3 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.